Display options
Cite
Peixoto RD, Renouf DJ, Gill S, et al. Relationship of ethnicity and overall survival in patients treated with sorafenib for advanced hepatocellular carcinoma. J Gastrointest Oncol. 2014;5(4):259-64doi: 10.3978/j.issn.2078-6891.2014.036.
Peixoto, R. D., Renouf, D. J., Gill, S., Cheung, W. Y., & Lim, H. J. (2014). Relationship of ethnicity and overall survival in patients treated with sorafenib for advanced hepatocellular carcinoma. Journal of gastrointestinal oncology, 5(4), 259-64. https://doi.org/10.3978/j.issn.2078-6891.2014.036
Peixoto, Renata D'Alpino, et al. "Relationship of ethnicity and overall survival in patients treated with sorafenib for advanced hepatocellular carcinoma." Journal of gastrointestinal oncology vol. 5,4 (2014): 259-64. doi: https://doi.org/10.3978/j.issn.2078-6891.2014.036
Peixoto RD, Renouf DJ, Gill S, Cheung WY, Lim HJ. Relationship of ethnicity and overall survival in patients treated with sorafenib for advanced hepatocellular carcinoma. J Gastrointest Oncol. 2014 Aug;5(4):259-64. doi: 10.3978/j.issn.2078-6891.2014.036. PMID: 25083298; PMCID: PMC4110502.
Copy Download .nbib Format: NLM
Share it on

J Gastrointest Oncol. 2014 Aug;5(4):259-64. doi: 10.3978/j.issn.2078-6891.2014.036.

Relationship of ethnicity and overall survival in patients treated with sorafenib for advanced hepatocellular carcinoma.

Journal of gastrointestinal oncology

Renata D'Alpino Peixoto, Daniel J Renouf, Sharlene Gill, Winson Y Cheung, Howard J Lim

Affiliations

  1. BC Cancer Agency, Canada.

PMID: 25083298 PMCID: PMC4110502 DOI: 10.3978/j.issn.2078-6891.2014.036

Abstract

BACKGROUND: Although both the SHARP and the Asian-Pacific trials showed improved overall survival (OS) for sorafenib, the magnitude of benefit was substantially less for Asians, who have a higher prevalence of hepatitis B viral (HBV) infection. Whether the worse prognosis is related to ethnicity or to the etiology of hepatocellular carcinoma (HCC) remains unclear. The aim of this study was to identify prognostic factors among patients with HCC who received sorafenib in British Columbia (BC), which has a sizeable Asian population.

METHODS: A total of 255 consecutive patients with advanced HCC who initiated sorafenib from January 2008 to February 2013 were identified using our pharmacy database. Clinicopathological variables and outcomes were retrospectively collected. Prognostic factors were assessed by univariate and multivariate analyses.

RESULTS: Median age was 63 years, 80.2% were men, and 38% were Asian. Among them, 34.5% had HBV and 29.8% had hepatitis C viral (HCV) infection. In addition, 68.6% had cirrhosis and 45.9% had liver-limited disease. Median progression-free and OS were 3.7 [95% confidence interval (CI): 3.3-4.2] and 7.5 months (95% CI: 5.7-9.2), respectively. On multivariate analysis, Eastern Cooperative Oncology Group performance status (ECOG PS) and HCV positivity correlated with better OS (P<0.001 and 0.04, respectively), but ethnicity did not (P=0.622).

CONCLUSIONS: When treated with sorafenib at the same institution, Asians and Caucasians with advanced HCC had similar OS. ECOG PS and HCV were the only significant prognostic factors. A higher proportion of HCV positivity might explain why the SHARP trial achieved better OS when compared to the Asian-Pacific trial.

Keywords: Hepatocellular carcinoma (HCC); ethnicity; sorafenib

References

  1. N Engl J Med. 2008 Jul 24;359(4):378-90 - PubMed
  2. Lancet Oncol. 2009 Jan;10(1):25-34 - PubMed
  3. Cancer Sci. 2008 Jan;99(1):159-65 - PubMed
  4. Dig Dis Sci. 2012 May;57(5):1122-9 - PubMed
  5. Cancer. 2009 Jan 15;115(2):428-36 - PubMed
  6. Clin Cancer Res. 2009 Aug 1;15(15):4806-14 - PubMed
  7. J Cancer Educ. 2007 Winter;22(4):266-72 - PubMed
  8. Oncogene. 2001 May 3;20(20):2606-10 - PubMed
  9. Int J Clin Pract. 2012 Jul;66(7):675-83 - PubMed
  10. CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 - PubMed
  11. J Hepatol. 2012 Oct;57(4):821-9 - PubMed
  12. Cancer Res. 2004 Oct 1;64(19):7099-109 - PubMed
  13. J Clin Gastroenterol. 2013 Jul;47 Suppl:S2-6 - PubMed

Publication Types